ondensetron all peadiatrics and drops concentration
Reading File
Finding Sources
Searching the Web
ondansetron pediatric oral drops concentration mg/ml dosing
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive information. Here is the full clinical reference:
Ondansetron in Paediatrics - Complete Reference
Drug Overview
Ondansetron is a selective 5-HT3 (serotonin) receptor antagonist. It blocks peripheral vagal afferents in the GI tract and central receptors in the chemoreceptor trigger zone, suppressing nausea and vomiting. It is the first-line antiemetic in children.
Available Formulations & Concentrations
| Formulation | Concentration |
|---|---|
| Oral solution / drops / syrup | 4 mg / 5 mL (0.8 mg/mL) |
| Oral solution (some brands) | 2 mg / mL |
| ODT (orally disintegrating tablet) | 4 mg, 8 mg |
| Tablet | 4 mg, 8 mg |
| IV / IM injection | 2 mg/mL |
Drop concentration most commonly cited: 4 mg/5 mL oral solution. Some preparations (e.g. hospital compounded) come as 2 mg/mL. Always confirm the specific product concentration before dosing.
Paediatric Dosing
1. Acute Gastroenteritis / General Nausea & Vomiting (most common use)
| Patient Weight | Dose | Route |
|---|---|---|
| 8 - 15 kg | 2 mg | PO or IV |
| 15.1 - 30 kg | 4 mg | PO or IV |
| > 30 kg | 8 mg | PO or IV |
Weight-based alternative: 0.15 mg/kg (up to 8 mg max) PO or IV - this is the dose most widely cited in emergency medicine.
- ROSEN's Emergency Medicine confirms: "Ondansetron 0.15 mg/kg up to 8 mg orally (PO) or IV is safe and potentially cost-effective due to its impact in decreasing IV fluid therapy needs and hospitalization rates in the pediatric population."
- A 2016 meta-analysis showed ondansetron vs. placebo improved cessation of vomiting at 1 hour, reduced failure of oral rehydration, reduced need for IV fluids, and reduced hospitalization rates.
2. Post-Operative Nausea & Vomiting (PONV) Prophylaxis
| Indication | Dose | Route | Timing |
|---|---|---|---|
| PONV prophylaxis (general) | 50-100 mcg/kg (0.05-0.1 mg/kg) | IV | End of surgery |
| High-risk POV (e.g. strabismus) | 0.1 mg/kg | IV | Toward end of case |
| Max single dose | 4 mg (paediatric) | IV | - |
- Barash Clinical Anesthesia: "The combination of ondansetron (50 to 100 mcg/kg) and dexamethasone (0.15 mg/kg) as dual prophylaxis is most strongly supported in the literature."
- Miller's Anesthesia: "Dexamethasone 0.1-0.2 mg/kg at the beginning of the procedure and ondansetron 0.1 mg/kg toward the end of the case is the recommended strategy."
3. Chemotherapy-Induced Nausea & Vomiting (CINV)
| Age | Dose | Frequency |
|---|---|---|
| 4-11 years (moderate emetic risk chemo) | 4 mg 30 min before chemo, then 4 & 8 hrs after | Then 4 mg every 8 hrs for 1-2 days |
| ≥ 12 years | 8 mg 30 min before chemo | Then 8 mg at 8 hrs; then 8 mg every 12 hrs for 1-2 days |
| 6 months - 17 years (IV, based on BSA) | 5 mg/m² IV before chemo (max 8 mg) | Then 4 mg PO every 12 hrs x 5 days |
4. Age Cutoffs - Summary
| Age | Status |
|---|---|
| < 6 months | Not recommended (insufficient data) |
| 6 months - 2 years | Use with caution; weight-based dosing |
| 2 - 12 years | Standard weight-based dosing |
| ≥ 12 years | Adult dosing may apply (8 mg doses) |
Oral Solution / Drops - Practical Dosing Volume
Using standard 4 mg/5 mL (0.8 mg/mL) concentration:
| Dose Needed | Volume |
|---|---|
| 2 mg | 2.5 mL |
| 4 mg | 5 mL |
| 8 mg | 10 mL |
Using 2 mg/mL concentration:
| Dose Needed | Volume |
|---|---|
| 2 mg | 1 mL |
| 4 mg | 2 mL |
| 8 mg | 4 mL |
Safety Considerations in Children
- QT prolongation: FDA issued a safety advisory in 2011. Risk of ventricular arrhythmia is ~3 per 100,000 paediatric patients; increases with underlying cardiac conditions (congenital long QT, heart failure, bradyarrhythmias).
- Caution / ECG monitoring in: congenital long QT syndrome, CHF, bradyarrhythmias, patients on other QT-prolonging drugs.
- Electrolytes: Correct hypokalaemia or hypomagnesaemia before giving ondansetron.
- Hepatic impairment: Total daily dose should not exceed 8 mg in moderate-severe hepatic impairment.
- Renal impairment: No dose adjustment required.
- Side effects: Headache, diarrhoea (most common); constipation, dizziness.
- Note: Studies showing benefit in acute gastroenteritis were all in children with at least mild dehydration. In well-hydrated children with no dehydration, benefit over placebo was not demonstrated.
Key Point on ODT vs. Oral Solution
The ODT (orally disintegrating tablet) is convenient and avoids the need to measure liquid. Evidence very weakly favours ODT over oral solution, but both are acceptable. The oral solution/drops are preferred for younger children or those unable to handle tablets.
Sources: ROSEN's Emergency Medicine (9e); Tintinalli's Emergency Medicine; Barash Clinical Anesthesia (9e); Miller's Anesthesia (10e); Children's Mercy Hospital AGE Protocol; Medsafe NZ Data Sheet.
genrate a pdf for all antibiotics and calculation for weight in ml
Asking for Preferences
Reading File
Running Command
You've run out of free credits. Sign up for a free account to continue using Orris.
This is a shared conversation. Sign in to Orris to start your own chat.